Clinical trial
Immuno-persistence Study of A Bivalent Human Papillomavirus (Type 16, 18) Recombinant Vaccine (E.Coli) in Healthy Female Subjects Aged 9 to 17 Years
NCT04704908 is registered in ClinicalTrials.gov with Jun Zhang as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Immuno-persistence Study of A Bivalent Human Papillomavirus (Type 16, 18) Recombinant Vaccine (E.Coli) in Healthy Female Subjects Aged 9 to 17 Years
- Lead sponsor
- Jun Zhang
- Phase
- Observational
- Overall status
- Unknown status
- Start date
- February 6, 2021
- Completion date
- December 31, 2023
- Enrollment
- 979 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
cervical cancer, cervical intraepithelial neoplasia, persistent infection, vaginal intraepithelial neoplasia, vulvar intraepithelial neoplasia